Your AI-Trained Oncology Knowledge Connection!
Heather A. Wakelee, MD, discusses recent research investigating antiangiogenic agents and checkpoint inhibitors in the frontline for patients with <em>EGFR</em>-positive non—small cell lung cancer. The most promising data were demonstrated in the phase III IMpower150 trial.
Heather A. Wakelee, MD, discusses the use of osimertinib as a frontline treatment option for patients with <em>EGFR</em>-positive lung cancer.
Heather A. Wakelee, MD, discusses a study utilizing liquid biopsies in patients with non-small cell lung cancer who harbor EGFR mutations.
Published: August 13th 2019 | Updated:
Published: January 25th 2019 | Updated:
Published: June 14th 2016 | Updated:
